Company research / PRPH

ProPhase Labs, Inc. (PRPH)

CIK 0000868278 · OTC · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, ProPhase Labs, Inc. reported revenue of $4.34M. Revenue fell 35.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.85M.

Key ratios (year ended 2025-12-31)

31.9%
Gross margin
-415.4%
Operating margin
-339.3%
Net margin
-420.3%
Return on year-end equity
-35.8%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-10, first reflected in a filing dated 2026-06-01. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$3.85M$4.34M$6.77M$34.98M$122.65M$79.04M$14.51M$9.88M$13.13M$9.87M$4.21M
Cost of Revenue$3.20M$2.96M$6.92M$19.43M$51.99M$37.05M$9.91M$7.26M$8.35M$7.92M$3.21M
Gross Profit$645.0K$1.38M-$150.0K$15.56M$70.65M$41.99M$4.61M$2.62M$4.78M$1.95M$997.0K
R&D Expensen/a$107.0K$594.0K$1.40M$652.0K$520.0K$633.0K$332.0K$398.0K$431.0K$358.0K
Operating Income-$15.56M-$18.05M-$38.63M-$21.22M$23.59M$9.80M-$2.08M-$3.24M-$1.63M-$3.99M-$2.66M
Depreciation & Amortization$3.93M$4.83M$6.19M$6.05M$4.72M$3.23M$449.0K$398.0K$383.0K$337.0K$426.0K
EBITDA-$11.63M-$13.21M-$32.44M-$15.17M$28.31M$13.04M-$1.63M-$2.84M-$1.25M-$3.65M-$2.23M
Net Income-$22.46M-$14.74M-$53.36M-$16.78M$18.46M$6.27M-$2.12M-$3.15M-$1.74M$40.59M-$2.87M
EPS (Diluted)n/a-$1.74-$26.68-$0.98$1.02$0.40-$0.18n/a-$0.15$2.59-$0.17
Total Assets$57.41M$59.87M$63.20M$91.93M$87.65M$89.30M$31.41M$12.27M$20.74M$33.66M$12.80M
Total Liabilities$60.52M$56.36M$55.85M$42.54M$24.02M$30.67M$20.85M$1.04M$4.23Mn/an/a
Shareholders' Equity-$3.11M$3.51M$7.35M$49.38M$63.63M$58.63M$10.56M$11.23M$16.50M$31.85M$5.96M
Cash & Equivalents$20.0K$90.0K$678.0K$1.61M$9.11M$8.41M$6.82M$434.0K$1.55M$3.17M$441.0K
Operating Cash Flow-$5.54M-$8.34M-$17.54M-$11.89M$28.55M-$13.62M-$2.59M-$841.0K-$2.12M-$2.84M-$472.0K
Capital Expendituresn/a$0$906.0K$2.08M$3.92M$4.23M$1.69M$228.0K$140.0K$208.0K$651.0K
Free Cash Flown/a-$8.34M-$18.44M-$13.97M$24.63M-$17.85M-$4.28M-$1.07M-$2.26M-$3.05M-$1.12M
Share Repurchasesn/an/a$0$588.0K$2.15M$917.0Kn/an/an/a$16.28Mn/a
Dividends Paidn/an/an/a$0$9.35M$4.55Mn/a$5.82M$11.70Mn/an/a
Shares Outstanding14.02M8.97M2.99M18.05M16.21M15.49M11.60Mn/an/an/an/a
Dividends Per Sharen/an/an/an/an/a$0.30n/an/an/an/an/a
Weighted Average Diluted Sharesn/a8.49M2.00M17.21M18.65M18.39M11.60Mn/a11.40M15.70M17.08M
EPS (Basic)n/a-$1.74-$26.68-$0.98$1.17$0.41-$0.18-$0.27-$0.15$2.61-$0.17